United States, Nov. 26 -- GE HealthCare announced that it has received FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology. Powered by deep learning, Pristina Recon DL sets a new standard in image definition and sharpness.Breast cancer remains one of the most common cancers among women, with one in eight expected to face a diagnosis in their lifetime and an estimated 1.1 million breast cancer-related deaths projected annually by 2050. As the burden of disease continues to rise, the advancement of AI-powered technologies holds remarkable promise in supporting early detection, accurate diagnosis and helping elevate the quality of care.Pristina Recon DL leverages two deep learning model...